[ad_1]
DUBLIN – (Business Wire) – The "No
Alcoholic Foie Gras (NAFLD) – Pipeline Insight, 2019 "
drug pipelines was added to ResearchAndMarkets.com & # 39; s
offer.
Non-Alcoholic Foie Gras (NAFLD) – Pipeline Insight, 2019
The report provides a comprehensive overview of the pipeline (under development)
therapeutic scenario and growth prospects for non-alcoholic fats
Development of Liver Diseases (NAFLD).
The report provides detailed coverage of the pipeline landscape for this
mechanism of action, with data from multiple sources with
complete pipeline badysis by stage of development, badociated
indications, route of administration and type of molecule.
Pipeline therapeutic development coverage provides a descriptive product
profiles including (but not limited to) the description of the drug, the
development and R & D activities encompbading clinical and preclinical activities.
studies, designations, collaborations, license agreements, grants,
technologies and patent details.
Report evaluates active non-alcoholic fatty liver disease (NAFLD)
pipeline products by stage of development, type of product, type of molecule,
and route of administration.
Key topics covered:
1. Introduction to the report
2. Overview of Non-Alcoholic Fatty Liver Disease (NAFLD)
3. Therapeutics Pipeline
-
An overview of pipeline products for non-alcoholic fatty liver disease
(NAFLD)
4. Comparative badysis
5. Products in clinical phase
-
Product Description
-
Research and development
-
Product development activities
6. Products in preclinical and discovery phase
-
Product Description
-
Research and development
-
Product development activities
7. Therapeutic evaluation
-
Evaluation by way of administration
-
Evaluation by stage and route of administration
-
Evaluation by molecule type
-
Evaluation by stage and type of molecule
8. Inactive products
8.1 Name of the drug: Name of the company
-
Product Description
-
Research and development
-
Product development activities
Companies mentioned (partial list)
-
Allergan Plc
-
Arisaph Pharmaceuticals Inc
-
AstraZeneca Plc
-
Betagenon AB
-
Bird Rock Bio Inc
-
Can-Fite BioPharma Ltd
-
Cerenis Therapeutics Holding SA
-
Conatus Pharmaceuticals Inc
-
Cyma Bay Therapeutic Inc
-
Daewoong Pharmaceutical Co Ltd
For more information on this report on Drug Pipelines, visit https://www.researchandmarkets.com/research/rmb9lk/non_alcoholic?w=4
See the source version on businesswire.com: https://www.businesswire.com/news/home/20190128005395/fr/
ResearchAndMarkets.com
Laura Wood, Senior Press Secretary
[email protected]
For
E.S.T Office Hours: 1-917-300-0470
For a toll-free call to the United States and Canada
1-800-526-8630
For GMT office hours, call + 353-1-416-8900
Related
Topics: Liver
and kidney disorders
[ad_2]
Source link
